Comparison of Fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 4, 1998, Pages 899-902

  Clemons, Karl V ^a   Stevens, David A ^b  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCD; AMBI; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYPTOCOCCOSIS; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; INTRAVENOUS DRUG ADMINISTRATION; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 0031978725     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.4.899     Document Type: Article

References (20)

1. Adler-Moore, J. P., S. Chiang, A. Satorius, D. Guerra, B. McAndrews, E. J. McManus, and R. T. Proffitt. 1991. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). J. Antimicrob. Chemother. 28(Suppl. B):63-71.
2. Albert, M. M., T. L. Stahl-Carroll, M. F. Luther, and J. R. Graybill. 1995. Comparison of liposomal amphotericin B to amphotericin B for treatment of murine cryptococcal meningitis. J. Mycol. Med. 5:1-6.
3. Clark, J. M., R. R. Whitney, S. J. Olsen, R. J. George, M. R. Swerdel, L. Kunselman, and D. P. Bonner. 1991. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob. Agents Chemother. 35:615-621.
4. Clemons, K. V., E. Brummer, and D. A. Stevens. 1994. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob. Agents Chemother. 38:460-464.
5. Clemons, K. V., and D. A. Stevens. 1991. Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis. Antimicrob. Agents Chemother. 35:2144-2146.
6. Clemons, K. V., and D. A. Stevens. 1991. Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis. Antimicrob. Agents Chemother. 35:1829-1833.
7. Clemons, K. V., and D. A. Stevens. 1993. Comparison of a liposomal amphotericin formulation (AmBisome) and deoxycholate amphotericin (Fungizone) for the treatment of paracoccidioidomycosis. J. Med. Vet. Mycol. 31:387-394.
8. Clemons, K. V., and D. A. Stevens. 1992. Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis. J. Antimicrob. Chemother. 30:353-363.
9. Clemons, K. V., and D. A. Stevens. 1993. Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. J. Antimicrob. Chemother. 32:465-472.
10. Coker, R., D. Tomlinson, and J. Harris. 1991. Successful treatment of cryptococcal meningitis with liposomal amphotericin B after failure of treatment with fluconazole and conventional amphotericin B. AIDS 5:231-232.
11. Gallis, H. A., R. H. Drew, and W. W. Pickard. 1990. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:308-329.
12. Guo, L. S. S., R. M. Fielding, D. D. Lasic, R. L. Hamilton, and D. Mufson. 1991. Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs. Int. J. Pharm. 75:45-54.
13. Hiemenz, J. W., and T. J. Walsh. 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22(Suppl. 2):S133-S144.
14. Hostetler, J. S., K. V. Clemons, L. H. Hanson, and D. A. Stevens. 1992. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob. Agents Chemother. 36:2656-2660.
15. Janoff, A. S., L. T. Boni, M. C. Popescu, S. R. Minchey, P. R. Cullis, T. D. Madden, T. Taraschi, S. M. Gruner, E. Shyamsunder, M. W. Tate, R. Mendelsohn, and D. Bonner. 1988. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc. Natl. Acad. Sci. USA 85:6122-6126.
16. Lister, J. 1996. Amphotericin B lipid complex (Abelcet) in the treatment of invasive mycoses: the North American experience. Eur. J. Haematol. 56(Suppl. 57):18-23.
17. Perfect, J. R., and K. A. Wright. 1994. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. J. Antimicrob. Chemother. 33:73-81.
18. Proffitt, R. T., A. Satorius, S. Chiang, L. Sullivan, and J. P. Adler-Moore. 1991. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J. Antimicrob. Chemother. 28(Suppl. B):49-61.
19. Sharkey, P. K., J. R. Graybill, E. S. Johnson, S. G. Hausrath, K. B. Pollard, A. Kolokathis, D. Mildvan, P. Fan-Havard, R. H. K. Eng, T. F. Patterson, J. C. Pottage, Jr., M. S. Simberkoff, J. Wolf, R. D. Meyer, R. Gupta, L. W. Lee, and D. S. Gordon. 1996. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patient with AIDS. Clin. Infect. Dis. 22:315-321.
20. Sokal, R. R., and F. J. Rohlf. 1981. In Biometry, 2nd ed., p. 432-435. W. H. Freeman & Co., San Francisco, Calif.